Glenmark Pharmaceuticals Ltd.'s arm, Glenmark Specialty SA, has inked a licensing pact with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co for KN035 (Envafolimab), a cancer treatment. The agreement grants Glenmark licensing rights for KN035 in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America.